Brief: Sandoz Announces Partnership Agreement With Samsung Bioepis
March 18 (Reuters) - SANDOZ GROUP AG SDZ.S: ANNOUNCES PARTNERSHIP AGREEMENT WITH SAMSUNG BIOEPIS ON UP TO FIVE BIOSIMILARS, FURTHER EXPANDING ITS LEADING PIPELINE TO UP TO 32 ASSETS TO HAVE EXCLUSIVE GLOBAL COMMERCIALIZATION RIGHTS EXCEPT SELECT ASIAN MARKETS FINANCIAL DETAILS OF PARTNERSHIP AGREEMENT REMAIN CONFIDENTIAL Source text: ID:nEQ39SQTWa Further company coverage: SDZ.S (Gdansk Newsroom) ((((gdansk.newsroom@thomsonreuters.com ; +48 587785269; ));;))
Recent news on Sandoz AG
See all newsPfizer dismissed from US states' drug price-fixing lawsuit (updated)
Pfizer dismissed from US states' drug price-fixing lawsuit
Factbox: Major investment pledges at Choose France summit
Press Digest: Financial Times - June 1
Media: Sandoz warns cheap Chinese imports threaten Europe’s antibiotic supply- FT